Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load.
Arase Y, Suzuki Y, Suzuki F, Akuta N, Sezaki H, Kawamura Y, Kobayashi M, Imai N, Seko Y, Hosaka T, Matsumoto N, Saito S, Ikeda K, Kobayashi M, Kumada H. Arase Y, et al. Among authors: imai n. Hepatol Res. 2012 Aug;42(8):750-6. doi: 10.1111/j.1872-034X.2012.00982.x. Epub 2012 Mar 26. Hepatol Res. 2012. PMID: 22776551
Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer.
Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Ikeda K, et al. Among authors: imai n. Hepatol Res. 2010 Dec;40(12):1168-75. doi: 10.1111/j.1872-034X.2010.00720.x. Epub 2010 Sep 16. Hepatol Res. 2010. PMID: 20849431
Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Imai N, et al. Oncology. 2011;80(3-4):188-94. doi: 10.1159/000328749. Epub 2011 Jun 27. Oncology. 2011. PMID: 21709428
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Kawamura Y, et al. Among authors: imai n. Am J Gastroenterol. 2012 Feb;107(2):253-61. doi: 10.1038/ajg.2011.327. Epub 2011 Oct 18. Am J Gastroenterol. 2012. PMID: 22008893
Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.
Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Hsieh SD, Ogawa K, Tanabe M, Tsuji H, Kobayashi T. Arase Y, et al. Among authors: imai n. Hepatol Res. 2012 Mar;42(3):264-72. doi: 10.1111/j.1872-034X.2011.00915.x. Epub 2011 Dec 19. Hepatol Res. 2012. PMID: 22175908
838 results